ProMetic Life Sciences Inc. (PLI) Given “Outperform” Rating at Scotiabank
Several other research firms also recently commented on PLI. Bloom Burton restated a hold rating on shares of ProMetic Life Sciences in a report on Thursday, October 13th. Royal Bank Of Canada restated an outperform rating and set a C$4.70 price objective on shares of ProMetic Life Sciences in a report on Wednesday, November 16th. TD Securities restated a speculative buy rating and set a C$4.50 price objective on shares of ProMetic Life Sciences in a report on Thursday, October 27th. Canaccord Genuity lifted their target price on ProMetic Life Sciences from C$4.50 to C$4.75 and gave the company a buy rating in a research report on Friday, November 18th. Finally, CIBC cut their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. ProMetic Life Sciences has an average rating of Buy and a consensus price target of C$4.84.
Shares of ProMetic Life Sciences (TSE:PLI) opened at 2.54 on Tuesday. The company has a 50-day moving average price of $2.87 and a 200-day moving average price of $2.92. ProMetic Life Sciences has a 1-year low of $1.88 and a 1-year high of $3.62. The company’s market cap is $1.58 billion.
COPYRIGHT VIOLATION NOTICE: “ProMetic Life Sciences Inc. (PLI) Given “Outperform” Rating at Scotiabank” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark law. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/11/23/prometic-life-sciences-inc-pli-given-outperform-rating-at-scotiabank.html.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.